Clinical Trial Update: Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR [Phase 2]

View source ↗

Summary

Phase 2 window-of-opportunity trial evaluating dasatinib in operable triple-negative breast cancer; trial status terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Breast Neoplasms, Triple Negative Breast Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2022-02-25